LONDON, ONTARIO--(Marketwire - August 12, 2008) - Stellar Pharmaceuticals Inc. ("Stellar" or the "Company") (TSX VENTURE: SLX)(OTCBB: SLXCF) today announced that for the six month period ended June 30, 2008, total operating revenues improved by 20.7%. This improvement was driven by increased international sales for NeoVisc (up 160.7%), while cost of products sold for the period improved to 23.5% of product sales compared to 27.8% of product sales in the same period in 2007. The reduction in cost of products sold was a result of a decrease in the cost of materials used in the manufacturing process, as well as healthier production yields. These positive operating changes resulted in a gross profit increase of 29.2% over the same six month period in 2007.
